Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.
Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P; GEMRITUX Study Group.
J Am Soc Nephrol. 2017 Jan;28(1):348-358. doi: 10.1681/ASN.2016040449. Epub 2016 Jun 27.
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.
Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B.
Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. eCollection 2024 Sep.
Segmental membranous nephropathy.
Choung HYG, Goldman B.
Clin Exp Nephrol. 2021 Jul;25(7):700-707. doi: 10.1007/s10157-021-02056-1. Epub 2021 Mar 23.
Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy.
Madan A, Yalavarthy R, Kim DK, Moon JY, Park I, Mandayam S, Cortazar F, Kim SG, Enstrom A, Thomas H, Li J, Peng SL, Chen YC, Sanders J, Egbuna O, Tumlin J; AIS-D03 RUBY-3 Study Group.
Kidney Int Rep. 2025 Nov 3;11(1):106-116. doi: 10.1016/j.ekir.2025.10.029. eCollection 2026 Jan.
Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases.
Dixon BP, Greenbaum LA, Huang L, Rajan S, Ke C, Zhang Y, Li L.
Kidney Int Rep. 2023 Aug 25;8(11):2284-2293. doi: 10.1016/j.ekir.2023.08.033. eCollection 2023 Nov.
Anti-Neuron-Derived Neurotrophic Factor Antibodies in Secondary Membranous Nephropathy Caused by Syphilis: A Case Report.
Honda D, Okunaga I, Omote D, Inoue H, Yamasaki K, Wakabayashi H, Suzuki M, Aizawa M, Tomita S, Ikeda JI, Asanuma K.
Am J Kidney Dis. 2024 Aug;84(2):250-254. doi: 10.1053/j.ajkd.2024.02.007. Epub 2024 Mar 22.
Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease.
Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, Kretzler M, Pruijm M, Schytz PA, Tuttle KR.
Nephrol Dial Transplant. 2025 Oct 30;40(11):2182-2192. doi: 10.1093/ndt/gfaf114.
Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study.
Rovin BH, Boxhammer R, Thakur A, Ronco PM.
Kidney Int Rep. 2022 Sep;7(9):2086-2090. doi: 10.1016/j.ekir.2022.05.031. Epub 2022 Jun 10.
Safety and efficacy of sirolimus combined with cyclosporine in primary membranous nephropathy: a randomized controlled trial.
Wang F, Yang C, Shu Y, Lin CX, Yao Y, Li Y, Zhang YM, Wang X, Meng LQ, Cheng XY, Liu G, Zhao MH, Cui Z.
BMC Med. 2025 May 30;23(1):323. doi: 10.1186/s12916-025-04173-0.
Elevated plasma levels of acute phase proteins in mesangioproliferative glomerulonephritis, membranous nephropathy and IgA nephropathy.
Tencer J, Thysell H, Westman K, Rippe B.
Scand J Urol Nephrol. 1995 Mar;29(1):5-9. doi: 10.3109/00365599509180531.
